In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials (PDQ®)

Page Options

  • Print This Page
  • Email This Document
Clinical Trial Questions?
Get Help:
LiveHelp online chat

Clinical Trials (PDQ®)

Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

Basic Trial Information
Trial Description
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIBiomarker/Laboratory analysis, TreatmentActiveUnder 22NCINCI-2012-00703
CDR0000728296, COG-ACNS1022, ACNS1022, U10CA098543, NCT01553149

Trial Description


This randomized phase II trial studies low-dose or high-dose lenalidomide to see how well it works in treating younger patients with recurrent, refractory, or progressive juvenile pilocytic astrocytomas or optic nerve pathway gliomas. Lenalidomide may stop the growth of tumor cells by blocking blood flow to the tumor.

Further Study Information


I. To determine the objective response rate in children with recurrent, refractory, or progressive juvenile pilocytic astrocytomas and optic pathway gliomas who are treated with Regimen A low-dose (20 mg/m²/dose) or Regimen B high-dose (115 mg/m²/dose) lenalidomide.


I. To estimate the event-free survival (EFS) (based on standard two-dimensional tumor measurements, determined by each institution) of children with recurrent, refractory, or progressive juvenile pilocytic astrocytomas and optic pathway gliomas who are treated with lenalidomide.

II. To compare response categories and EFS across the 3 magnetic resonance (MR) sequences (T2-weighted, fluid attenuated inversion recovery [FLAIR], T1-weighted post-contrast).

III. To correlate steady-state pharmacokinetics of lenalidomide (1 sample obtained between Days 5-21) with objective response and EFS.

IV. To evaluate toxicities of long-term lenalidomide use.

OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.

ARM I (regimen A): Patients receive low-dose lenalidomide orally (PO) once daily (QD) on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.

ARM II (regimen B): Patients receive high-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.

Patients undergo blood sample collection between days 5-21 during course 1 for pharmacokinetic studies.

After completion of study treatment, patients are followed up for up to 5 years.

Eligibility Criteria

Inclusion Criteria:

  • Patients must have a pilocytic astrocytoma or optic pathway glioma that has relapsed, progressed, or become refractory to conventional therapy; patients with neurofibromatosis (NF-1) are eligible
  • Patients must have histologic verification of malignancy; histologic confirmation for patients with optic pathway gliomas will not be required
  • Patients must have measurable residual disease, defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI); for a lesion to be considered measurable, it must be at least twice the slice thickness on MRI (i.e., visible on more than one slice)
  • To document the degree of residual tumor, the following must be obtained:
  • All patients must have a brain MRI with and without contrast (gadolinium) within 1 week prior to study enrollment; for patients on steroids, baseline MRI scans must be performed after at least 1 week at a stable or decreasing dose of steroids
  • All patients with a history of spinal or leptomeningeal disease, and those patients with symptoms suspicious of spinal disease, must have a spine MRI with and without contrast (gadolinium) performed within 2 weeks prior to study enrollment
  • Patients must have been treated with two or fewer anti-cancer regimens, including chemotherapy, biologic agents, immunotherapy, vaccines, monoclonal antibodies, or radiation therapy
  • At least one prior treatment regimen must have included carboplatin
  • Patients who have received prior radiation therapy for this tumor are eligible
  • Patients must have a body surface area (BSA) ≥ 0.4 m² at the time of study enrollment
  • Patients must have a Lansky or Karnofsky performance status score of ≥ 60%; use Karnofsky for patients> 16 years of age and Lansky for patients ≤ 16 years of age
  • Peripheral absolute neutrophil count (ANC) ≥ 1,000/μL
  • Platelet count ≥ 100,000/μL (transfusion independent)
  • Hemoglobin ≥ 8.0 g/dL (may receive red blood cell [RBC] transfusions)
  • Creatinine clearance or radioisotope glomerular filtration rate(GFR) ≥ 70 mL/min OR a serum creatinine based on age/gender as follows:
  • 0.4 mg/dL (1 month to < 6 months of age)
  • 0.5 mg/dL (6 months to < 1 year of age)
  • 0.6 mg/dL (1 to < 2 years of age)
  • 0.8 mg/dL (2 to < 6 years of age)
  • 1.0 mg/dL (6 to 10 years of age)
  • 1.2 mg/dL (10 to < 13 years of age)
  • 1.5 mg/dL (male) or 1.4 mg/dL (female) (13 to < 16 years of age)
  • 1.7 mg/dL (male) or 1.4 mg/dL (female) (≥ 16 years of age)
  • Total bilirubin ≤ 1.5 times upper limit of normal (ULN) for age
  • Serum glutamic pyruvate transaminase(SGPT) (alanine aminotransferase [ALT]) ≤ 110 U/L; for the purpose of this study, the ULN for SGPT is 45 U/L
  • Serum albumin ≥ 2 g/dL
  • No evidence of dyspnea at rest and a pulse oximetry > 94% if there is clinical indication for determination
  • Patients must be able to swallow intact capsules
  • Not pregnant or breastfeeding
  • Lactating females are not eligible unless they have agreed not to breastfeed their infants while receiving protocol therapy and for 28 days after the last dose of lenalidomide
  • Female patients of childbearing potential are not eligible unless they commit to complete abstinence or have been on 2 methods of birth control, including 1 highly effective method and 1 additional method at the same time (unless committing to complete abstinence of heterosexual intercourse), at least 28 days (4weeks) prior to study enrollment; sexually active females must also agree to remain on 2 methods of birth control during treatment (including during dose interruptions) and continuing for at least 28 days after the completion of protocol therapy; examples of methods of contraception are as follows:
  • Highly effective methods (must use at least 1):
  • Intrauterine device (IUD)
  • Hormonal (prescription birth control pills, injections, implants)
  • Tubal ligation
  • Partner's vasectomy
  • Additional effective methods:
  • Male condom
  • Diaphragm
  • Cervical cap
  • The two methods of birth control requirement applies to all sexually active females unless they have not had a menstrual period in the preceding 24 consecutive months or have undergone a hysterectomy or bilateral oophorectomy
  • Female patients of childbearing potential (including those who commit to complete abstinence) are not eligible unless they agree to ongoing pregnancy testing and counseling every28 days about pregnancy precautions and risks of fetal exposure
  • Male patients of child-fathering potential are not eligible unless they have agreed to use latex condoms during intercourse with a woman of childbearing potential while receiving treatment and for 28 days thereafter
  • Patients with a history of thromboembolism unrelated to a central line or patients with a known predisposition syndrome for thromboembolism are not eligible
  • Patients who have an uncontrolled or untreated infection are not eligible
  • Patients with known overt cardiac disease including, but not limited to, a history of myocardial infarction, severe or unstable angina, clinically significant peripheral vascular disease, Grade 2 or greater heart failure, or serious and inadequately controlled cardiac arrhythmia are not eligible
  • Patients with a significant systemic illness that is not well-controlled, in the opinion of the treating physician, are not eligible
  • See Disease Characteristics
  • Patients must have recovered (to common terminology criteria [CTC] v.4.0 ≤ Grade 1 unless indicated below) from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study, with the exception of alopecia, weight changes, and Grade I or II lymphopenia
  • Must not have received myelosuppressive chemotherapy within 3 weeks of entry onto this study(6 weeks if prior nitrosourea or mitomycin C)
  • At least 7 days after the last dose of a biologic agent; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur
  • At least 42 days after the completion of any type of immunotherapy, e.g., tumor vaccines
  • At least 3 half-lives of the antibody after the last dose of a monoclonal antibody
  • Patients must have had their last fraction of craniospinal radiotherapy (RT)≥ 6 months prior to study entry and their last fraction of focal RT ≥ 4 weeks prior to study entry; if the lesion used for on-study criteria is in the radiation field, there must be evidence of tumor progression after radiation therapy was completed
  • Study-specific limitations on prior therapy:
  • Patients who have received prior thalidomide are eligible if all acute thalidomide-related toxicity has resolved
  • Patients must not have received lenalidomide previously
  • Must not have received growth factor(s) within 2 weeks of entry onto this study
  • Patients who are receiving corticosteroids must be on a stable or decreasing dose for at least 1 week prior to baseline MRI
  • Concurrent cancer therapy, including chemotherapy, radiation therapy, immunotherapy, or biologic therapy, may NOT be administered to patients while on this study

Trial Contact Information

Trial Lead Organizations/Sponsors

National Cancer Institute

Katherine WarrenPrincipal Investigator

Trial Sites

 UAB Comprehensive Cancer Center
 Alyssa T Reddy Ph: 205-934-0309
 Phoenix Children's Hospital
 Jessica Boklan Ph: 602-546-0920
  Little Rock
 Arkansas Children's Hospital at the University of Arkansas for Medical Sciences
 David L Becton Ph: 501-364-7373
 Southern California Permanente Medical Group
 Robert M Cooper Ph: 626-564-3455
 City of Hope Comprehensive Cancer Center
 Anna B Pawlowska Ph: 800-826-4673
  Los Angeles
 Children's Hospital Los Angeles
 Leo Mascarenhas Ph: 323-361-4110
 Kaiser Permanente-Oakland
 Steven K Bergstrom Ph: 626-564-3455
 University of California Davis Cancer Center
 Jay Michael S Balagtas Ph: 916-734-3089
 Children's Hospital Colorado Center for Cancer and Blood Disorders
 Margaret E Macy Ph: 720-777-6672
 UF Health Cancer Center
 William B Slayton Ph: 352-273-8675
 Florida Hospital Cancer Institute at Florida Hospital Orlando
 Fouad M Hajjar Ph: 407-303-5623
  Saint Petersburg
 All Children's Hospital
 Gregory A Hale Ph: 727-767-2423
 Cancer Research Center of Hawaii
 Robert W Wilkinson Ph: 808-983-6090
 Mountain States Tumor Institute at St. Luke's Regional Medical Center
 Eugenia Chang Ph: 800-845-4624
 University of Chicago Cancer Research Center
 Charles M Rubin Ph: 773-834-7424
 University of Illinois Cancer Center
 Mary L Schmidt Ph: 312-355-3046
 Cardinal Bernardin Cancer Center at Loyola University Medical Center
 Ricarchito B Manera Ph: 708-226-4357
 Saint Jude Midwest Affiliate
 Pedro A De Alarcon Ph: 309-655-3258
 Riley's Children Cancer Center at Riley Hospital for Children
 Robert J Fallon Ph: 317-274-2552
 St. Vincent Indianapolis Hospital
 Bassem I Razzouk Ph: 317-338-2194
  Des Moines
 Blank Children's Hospital
 Wendy L Woods-Swafford Ph: 515-241-6729
 University of Kentucky Chandler Medical Center
 Lars M Wagner Ph: 859-257-3379
 Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
 Carlos Rodriguez-Galindo Ph: 866-790-4500
 Wayne State University
 Zhihong J Wang Ph: 313-576-9363
 Mayo Clinic Cancer Center
 Carola A. S. Arndt Ph: 507-538-7623
 University of Mississippi Cancer Clinic
 Gail C Megason Ph: 601-815-6700
  Kansas City
 Children's Mercy Hospital
 Kathleen A Neville Ph: 816-234-3265
  Saint Louis
 Cardinal Glennon Children's Hospital
 William S Ferguson Ph: 314-268-4000
 David C. Pratt Cancer Center at St. John's Mercy
 Bethany G. Sleckman Ph: 913-948-5588
 Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
 Joshua B Rubin Ph: 800-600-3606
  Las Vegas
 CCOP - Nevada Cancer Research Foundation
 Jonathan Bernstein Ph: 702-384-0013
New Mexico
 University of New Mexico Cancer Center
 Koh B Boayue Ph: 505-272-6972
New York
 Montefiore Medical Center
 Peter D Cole Ph: 718-904-2730
 Roswell Park Cancer Institute
 Martin L Brecher Ph: 877-275-7724
  New York
 Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
 Alice Lee Ph: 212-305-8615
 New York University Medical Center
 Jeffrey C Allen Ph: 212-263-4434
 SUNY Upstate Medical University Hospital
 Karol H Kerr Ph: 315-464-5476
North Carolina
  Chapel Hill
 Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
 Stuart H Gold Ph: 877-668-0683
 Blumenthal Cancer Center at Carolinas Medical Center
 Joel A Kaplan Ph: 704-355-2884
 Akron Children's Hospital
 Steven J Kuerbitz Ph: 330-543-3193
  Oklahoma City
 Oklahoma University Cancer Institute
 Rene Y McNall-Knapp Ph: 405-271-4272
 Penn State Children's Hospital
 Lisa M McGregor Ph: 717-531-6012
South Carolina
 BI-LO Charities Children's Cancer Center
 Nichole L Bryant Ph: 864-241-6251
South Dakota
  Sioux Falls
 Sanford Cancer Center at Sanford USD Medical Center
 Kayelyn J Wagner Ph: 605-328-1367
 St. Jude Children's Research Hospital
 Ibrahim A Qaddoumi Ph: 901-595-4644
 Vanderbilt-Ingram Cancer Center
 Adam Esbenshade Ph: 800-811-8480
 Dell Children's Medical Center of Central Texas
 Sharon K Lockhart Ph: 512-324-8022
 Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
 Naomi J Winick Ph: 214-648-7097
  Fort Worth
 Cook Children's Medical Center - Fort Worth
 Mary Meaghan P Granger Ph: 682-885-2103
 Dan L. Duncan Cancer Center at Baylor College of Medicine
 Jack M. Su Ph: 713-798-1354
  Salt Lake City
 Primary Children's Medical Center
 Phillip E Barnette Ph: 801-585-5270
 Children's Hospital and Regional Medical Center - Seattle
 Douglas S Hawkins Ph: 866-987-2000
 University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
 Kenneth B DeSantes Ph: 608-262-5223
 Royal Brisbane and Women's Hospital
 Timothy E Hassall Ph: 888-823-5923
 Royal Children's Hospital
 Helen Irving Ph: 888-823-5923
 Cancer Centre of Southeastern Ontario at Kingston General Hospital
 Mariana P Silva Ph: 613-544-2630
 Hopital Sainte Justine
 Yvan Samson Ph: 514-345-4931
 Montreal Children's Hospital at McGill University Health Center
 Sharon B Abish Ph: 514-412-4445
New Zealand
 Starship Children's Health
 Lochie R Teague Ph:  0800 728 436

Link to the current record.
NLM Identifer NCT01553149 processed this data on August 12, 2014

Note: Information about this trial is from the database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the record to standardize the names of study sponsors, sites, and contacts. only lists sites that are recruiting patients for active trials, whereas lists all sites for all trials. Questions and comments regarding the presented information should be directed to

Back to TopBack to Top